Table 1 Baseline demographical, disease, and barriers characteristics of participants stratified by group
Characteristic | Total Participants (n = 19) | Control (n = 11) | Treatment (n = 8) |
|---|---|---|---|
Demographics | |||
Age, mean, (SD) in yrs. | 20.5 (1.6) | 20.5 (1.6) | 20.5 (1.7) |
Gender (female), No (%) | 16 (84) | 11 (100) | 5 (63) |
Race, No, (%) | |||
White | 6 (32) | 4 (36) | 2 (25) |
Black | 11 (58) | 6 (55) | 5 (63) |
Asian | 1 (5) | – | 1 (13) |
Multiple | 1 (5) | 1 (9) | – |
Insurance type, No (%) | |||
Public | 7 (37) | 5 (45) | 2 (25) |
Private | 12 (63) | 6 (55) | 6 (75) |
cSLE | |||
Disease duration, yrs., (SD) | 4.8 (3.2) | 4 (3) | 5.4 (3.4) |
SLEDAIa, mean, (range) | 5 (0–10) | 5 (2–10) | 4.4 (0–9) |
SLICCb, No., (%) | 4 (40) | 3 (30) | 1 (12.5) |
Physician global, mean (range) | 0.9 (0–3.5) | 1 (0–3.5) | 0.6 (0–1.5) |
Nephritis, No. (%) | 8 (42) | 5 (45) | 3 (38) |
PROMIS fatigue, mean (SD) | 53 ± 3.0 | 57 ± 2.9 | 47 ± 3.2 |
PROMIS pain intensity, mean (SD) | 2.8 (2.3) | 3.6 ± 2.3 | 1.8 (1.9) |
No of Pillsc, mean (SD) | 7 (3.8) | 7 (3.5) | 8 (4.2) |
Presence of comorbidity (%) | 18 (95) | 11 (100) | 7 (88) |
Hypertension, No. (%) | 5 (26) | 3 (27) | 2 (25) |
Depression, No. (%) | 5 (26) | 3 (27) | 2 (25) |
Obesity, No. (%) | 10 (53) | 7 (66) | 3 (38) |
Barriersd, No (%) | |||
Forgetting | 15 (79) | 11 (100) | 4 (50) |
Taste | 13 (68) | 9 (81) | 4 (50) |
Side effects | |||
Current | 12 (63) | 8 (73) | 4 (50) |
Future | 11 (58) | 6 (55) | 5 (63) |
Fertility concerns | 11 (58) | 7 (64) | 4 (50) |
Treatment upsetting | 8 (42) | 6 (55) | 2 (25) |
Inconvenient | 7 (37) | 6 (55) | 1 (13) |
Cost | 7 (37) | 5 (45) | 2 (25) |